雷贝拉唑联合铝碳酸镁治疗胃食管返流病临床研究  

Clinical study of the effect of Rabeprazole and Hydrotalcite in the treatment of refractory gastroesophageal reflux disease

作　　者：彭火亮 吴玉波[1] 

机构地区：[1]惠州市龙门县人民医院,广东惠州516800

出　　处：《海南医学》2012年第8期29-31,共3页Hainan Medical Journal

摘　　要：目的探讨雷贝拉唑联合铝碳酸镁治疗胃食管返流病(GERD)临床疗效。方法选取GRED患者120例,随机分为观察组与对照组各60例,对照组给予铝碳酸镁治疗,观察组在对照组基础上加用雷贝拉唑治疗,对比两组临床症状改善情况与电子胃镜复查黏膜修复情况,并进行统计学分析。结果治疗6周,临床症状改善方面,观察组总有效率为95.0%(57例),对照组总有效率78.3%(47例),两组比较差异有统计学意义(P<0.01)。复查电子胃镜结果黏膜修复情况,观察组总有效率为96.7%(58例),对照组总有效率为81.7%(49例),两组比较差异有统计学意义(P<0.01)。结论雷贝拉唑联合铝碳酸镁治疗胃食管返流病,效果显著,疗效持久稳定,安全性高,毒副作用小,在临床中广泛推广切实可行。Objective To discuss the clinical effects of Rabeprazole combined with Hydrotalcite in the treatment of refractory gastroesophageal reflux disease（GERD）.Methods 120 patients with GERD were randomly divided into two groups.The control group（60 cases） were given hydrotalcite only,while the observation group（60 cases） were given Rabeprazole combined with Hydrotalcite.Then the improvements of clinical symptoms and gastric mucosa repair under electronic gastroscope were compared between the two groups.Results In the improvements of clinical symptom and gastric mucosa repair under electronic gastroscope,the total effective rate of the observation group（95.0%） was significantly higher than that of the control group（78.3%）,P0.01.Conclusion Rabeprazole combined with Hydrotalcite is effective for treating patients with GERD.The curative effect is reliable,persistent,and safe,with fewer side effects,which could be widely applied.

关 键 词：雷贝拉唑 铝碳酸镁 胃食管反流病 

分 类 号：R57[医药卫生—消化系统]